Cargando…

Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition

BACKGROUND: Hepatitis B virus (HBV) reactivation is a serious complication in patients with cancers and HBV infection undergoing immunosuppressant treatment or chemotherapy. However, the safety of anti-programmed cell death (PD) -1 and anti-programmed cell death-ligand 1 (PD-L1) therapy in these pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xuanye, Zhou, Yixin, Chen, Chen, Fang, Wenfeng, Cai, Xiuyu, Zhang, Xiaoshi, Zhao, Ming, Zhang, Bei, Jiang, Wenqi, Lin, Zuan, Ma, Yuxiang, Yang, Yunpeng, Huang, Yan, Zhao, Hongyun, Xu, Ruihua, Hong, Shaodong, Zhang, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873745/ https://www.ncbi.nlm.nih.gov/pubmed/31753012 http://dx.doi.org/10.1186/s40425-019-0808-5

Ejemplares similares

First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
por: Zhou, Yixin, et al.
Publicado: (2019)

Pre-Treatment Tumor Growth Rate Predicts Clinical Outcomes of Patients With Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD-1/PD-L1 Therapy
por: He, Li-na, et al.
Publicado: (2021)

Anti‐epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first‐line treatment for recurrent or metastatic nasopharyngeal carcinoma
por: Chen, Chen, et al.
Publicado: (2020)

Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy
por: Zhang, Xuanye, et al.
Publicado: (2021)

Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis
por: Zhou, Yixin, et al.
Publicado: (2018)

Continuation of anti-PD-1 therapy plus physician-choice treatment beyond first progression is not associated with clinical benefit in patients with advanced non-small cell lung cancer
por: Wang, Yixing, et al.
Publicado: (2023)

A CT‐based radiomics model to predict subsequent brain metastasis in patients with ALK‐rearranged non–small cell lung cancer undergoing crizotinib treatment
por: Jiang, Yongluo, et al.
Publicado: (2022)

Tumor response assessment by measuring the single largest lesion per organ in advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitor
por: He, Li-Na, et al.
Publicado: (2023)

Determinants of survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 therapy
por: Ali, Wael Abdullah Sultan, et al.
Publicado: (2021)

Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma by Targeting the Epidermal Growth Factor Receptor Combined with Gemcitabine Plus Platinum
por: Chen, Chen, et al.
Publicado: (2020)

PD-1 inhibition plus platinum-based chemotherapy (PBC) or PBC alone in the first-line treatment of locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma
por: Zhang, Xuanye, et al.
Publicado: (2022)

PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer
por: Yu, Hui, et al.
Publicado: (2021)

LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy
por: Luo, Linfeng, et al.
Publicado: (2023)

Machine learning-based risk model incorporating tumor immune and stromal contexture predicts cancer prognosis and immunotherapy efficacy
por: He, Li-Na, et al.
Publicado: (2023)

Pretreatment Serum Lactate Dehydrogenase and Metastases Numbers as Potential Determinants of Anti-PD-1 Therapy Outcome in Nasopharyngeal Carcinoma
por: Ali, Wael A. S., et al.
Publicado: (2023)

Hepatitis B virus reactivation in rheumatoid arthritis
por: Wu, Ya-Li, et al.
Publicado: (2022)

Ratio of C-Reactive Protein/Albumin is An Inflammatory Prognostic Score for Predicting Overall Survival of Patients with Small-cell Lung Cancer
por: Zhou, Ting, et al.
Publicado: (2015)

Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer
por: Fang, Wenfeng, et al.
Publicado: (2021)

Adjuvant therapy in completely resected, EGFR-mutant non-small cell lung cancer: a comparative analysis of treatment efficacy between EGFR-TKI and anti-PD-1/PD-L1 immunotherapy
por: Li, Zichun, et al.
Publicado: (2023)

Unsatisfied Reporting Quality of Clinical Trials Evaluating Immune Checkpoint Inhibitor Therapy in Cancer
por: Chen, Chen, et al.
Publicado: (2021)

The research of SARIMA model for prediction of hepatitis B in mainland China
por: Zhao, Daren, et al.
Publicado: (2022)

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
por: Zhang, Zhonghan, et al.
Publicado: (2019)

Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy‐free, first‐line treatment for PD‐L1‐positive non‐small cell lung cancer
por: Zhou, Yixin, et al.
Publicado: (2020)

A Phase I/II Open‐Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors
por: Ma, Yuxiang, et al.
Publicado: (2019)

PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival
por: Fang, Wenfeng, et al.
Publicado: (2015)

Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study
por: Zhao, Shen, et al.
Publicado: (2020)

Combinatorial assessment of ctDNA release and mutational burden predicts anti‐PD(L)1 therapy outcome in nonsmall‐cell lung cancer
por: Fang, Wenfeng, et al.
Publicado: (2020)

EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients
por: Zheng, Qiufan, et al.
Publicado: (2020)

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
por: Zheng, Qiufan, et al.
Publicado: (2020)

Recurrent paratyphoid fever A co-infected with hepatitis A reactivated chronic hepatitis B
por: Liu, Yanling, et al.
Publicado: (2014)

Hepatitis B and Hepatitis C Reactivation in the Biologic Era
por: Bojito-Marrero, Lizza, et al.
Publicado: (2014)

Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival
por: Chen, Kai-Lin, et al.
Publicado: (2015)

Terbinafine-Induced Hepatitis B Reactivation in a Patient With Chronic Hepatitis B
por: Shehi, Elona, et al.
Publicado: (2020)

Hepatitis B Virus Reactivation Increased the Risk of Developing Hepatic Failure and Mortality in Cirrhosis With Acute Exacerbation
por: Zhu, Ying, et al.
Publicado: (2022)

RFX1 participates in doxorubicin‐induced hepatitis B virus reactivation
por: Wang, Jie, et al.
Publicado: (2018)

Hepatitis B virus‐induced hyperactivation of B cells in chronic hepatitis B patients via TLR4
por: Li, Yang, et al.
Publicado: (2020)

Bortezomib Induced Hepatitis B Reactivation
por: Hussain, Salwa, et al.
Publicado: (2014)

Hepatitis B Virus Reactivation in Cancer Patients Undergoing Immune Checkpoint Inhibitors Therapy: A Systematic Review
por: Zhao, Jian, et al.
Publicado: (2022)

Serum hepatitis B core antibody as a biomarker of hepatic inflammation in chronic hepatitis B patients with normal alanine aminotransferase
por: Zhou, Jiyuan, et al.
Publicado: (2017)

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
por: Fang, Wenfeng, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_m6og9nogcnsd88b379u7s21g6o